RET inhibitor · small molecule
SY-5007
1 active trials, targeting RET. Not approved for any biomarker on marked.bio yet.
Counts only trials that select patients by one of the biomarkers on marked.bio, not every trial of this drug.
Biomarkers
| Biomarker | Active trials | All trials | Furthest active phase |
|---|---|---|---|
| RET fusion or mutation | 1 | 2 | Phase 3 |
Trials
1 of 2 trials shown
-
Phase III Study of SY-5007, a RET Inhibitor, in Patients With Locally Advanced or Metastatic RET Fusion-positive NSCLC
Previous tumor tissue or blood samples are confirmed as RET fusion positive by local laboratory testing. b.
RET fusion or mutationNon-Small Cell Lung Cancer
-
Phase I/II Study of SY-5007, a RET Inhibitor, in Patients With RET-altered Advanced Solid Tumor
…art: patients must have histological or cytological confirmed advanced solid tumours with RET alteration (fusion or mutation) and have progressed after standard therapy, or no standard or availa…
RET fusion or mutationNon-Small Cell Lung Cancer, Medullary Thyroid Cancer, Solid Tumor
No trials match these filters.